Teva (TEVA) Q2 Earnings and Sales Miss, Shares Down August 03, 2017

Posted August 05, 2017

ATR value of company was 0.78 and Relative Strength Index (RSI) was 18.79.

Teva Pharmaceutical Industries (TEVA) opened at 23.75 on Tuesday.

The volume of the particular stock is the shares bought and sold in a single trading day. On Monday, July 27 the stock rating was maintained by Maxim Group with "Buy".

Teva said the second quarter 2017 dividend would be 8.5 cents, down 75% from 34 cents in the first quarter of 2017. EPS breaks down the profitability of the company on a single share basis. Teva Pharmaceutical Industries Limited (TEVA) is a part of Healthcare sector and belongs to Drug Manufacturers - Other industry.

More news: Northwestern professor, Oxford employee sought in death of Chicago man
More news: The Duke of Edinburgh makes his final royal engagement
More news: Flash Flood Warning issued for Westmoreland Co, heavy rain possible

Teva Pharmaceutical Industries Limited (TEVA) waking on thin line between bulls and bears tracks and with several factors it's pulling towards optimistic side to some extend but some take to pessimistic side. Hersha Hospitality Trust has a one bull (extreme weakness) technical rating because it's trading below the 10 day, 50 day and 200 day simple moving averages while the 10-day moving average is below the 50-day moving average and the 50-day moving average is below the 200-day moving average. Like other generic drugmakers, Teva faces a tough pricing environment and increasing competition that is squeezing its already tight margins. (NASDAQ:MEET) lands the stock on today's most volatile list. This represents an increase of approximately 864% compared to the typical volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd.

In terms of earnings per share, 21 analysts have a 1.25 EPS mean target for the quarter ending Sep-17, for the quarter ending Dec-17, 21 analysts have a 1.41 EPS mean target and for the quarter ending Dec-17 there are 25 estimates of 4.75 EPS. Now the P/E of Teva Pharmaceutical Industries Limited (TEVA) stands at 224.06. In January, Teva had estimated earnings of $4.90 to $5.30 this year, with sales ranging from $23.8 billion to $24.5 billion. A stock with a beta more than 1 means high volatile and less than 1 means low volatile. It cut its full-year revenue expectations to $22.8 billion-$23.2 billion, from $23.8 billion-$24.5 billion. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.65 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of worldwide trademark & copyright legislation. Teva Pharma had 77 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald's price target would suggest a potential upside of 13.68% from the company's current price. CIBC reaffirmed a "buy" rating and issued a $43.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, April 7th. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges. Country Club Trust Company n.a. raised its stake in Teva Pharmaceutical Industries by 5.7% in the first quarter. The company has analyst rating of 2.50 on scale of 1-5. The stock presently has a consensus rating of "Hold" and an average target price of $42.23. The legal version of this news story can be read at https://www.com-unik.info/2017/08/04/teva-pharmaceutical-industries-limited-teva-downgraded-by-bidaskclub-updated-updated.html. "We have made important progress and it has been positive so far", he said, also deflecting questions from analysts on the prospects of splitting the company into two - generics and specialty drugs.